Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients

  • Elaine Cristina Morari
  • Andre Bacellar Costa Lima
  • Natassia Elena Bufalo
  • Janaina Luisa Leite
  • Fabiana Granja
  • Laura Sterian Ward
Original Paper


Purpose . A series of polymorphisms in germ-line DNA have been investigated in an effort to delineate polygenic models of cancer susceptibility and prognosis. As low-penetrance susceptibility genes may combine additively or multiplicatively and contribute to cancer incidence and to the response to chemotherapy, we studied GSTT1, GSTM1, GSTO2, GSTP1 and codon 72 of p53 genotype profiles in ovarian cancer patients. Methods . We compared 69 ovarian cancer patients with 222 control healthy women paired for ethnic and life-style characteristics. Outcome was evaluated in 29 stage III and IV patients submitted to a platinum-based chemotherapy followed-up for 6–29 months (17 ± 9 months). Results . GSTT1, GSTM1, GSTO2 and GSTP1 genes presented a similar genotype distribution, but codon 72 of p53 gene wild-type variant was less frequent in ovarian cancer patients than in controls (χ2; = 0.0004). Conclusions. We were unable to demonstrate any association between the GST genotypes studied and the risk of ovarian cancer but the inheritance of a heterozygous Arg/Pro genotype of p53 increased the risk of ovarian cancer more than 2.5 times (OR = 2.571; 95% CI = 1.453–4.550). There was no association of the studied genes to any clinical or pathological feature of the patients or to their response to chemotherapy.


Susceptibility Response to treatment Germline polymorphic inheritance 


  1. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I (2004) P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13:277–280CrossRefPubMedGoogle Scholar
  2. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, Niitsu Y (1996) Transfection of glutathione S-transferase (GST) –pi antisense complementary DNA increases the sensitivity of a colon cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 56:3577–3582PubMedGoogle Scholar
  3. Baxter SW, Thomas EJ, Campbell IG (2001) GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis 22:63–66CrossRefPubMedGoogle Scholar
  4. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44:266–270PubMedCrossRefGoogle Scholar
  5. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100:330–337Google Scholar
  6. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) P53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402CrossRefPubMedGoogle Scholar
  7. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233–2236PubMedCrossRefGoogle Scholar
  8. Board PG (1981) Biochemical genetics of glutathione S-transferase in man. Am J Hum Genet 33:36–43PubMedGoogle Scholar
  9. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997) The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMedGoogle Scholar
  10. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMedGoogle Scholar
  11. Clapper ML, Tigle H (2000) Genetic polymorphism and cancer risk. Curr Oncol Rep 2:251–256PubMedCrossRefGoogle Scholar
  12. Coughlin SS, Hall I (2002) Glutathione S-transferase olymorphisms and risk of ovarian cancer: a Huge review. Genet Med 4:250–257PubMedCrossRefGoogle Scholar
  13. Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T (2003) p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 82:111–120CrossRefPubMedGoogle Scholar
  14. Drummond SN, De Marco L, Pordeus Ide A, Barbosa AA, Gomez RS (2002) TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res 22:3379–3381PubMedGoogle Scholar
  15. Dulhunty A, Gage P, Curtis S, Chelvanayagam G, Board P (2001) The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. J Biol Chem 276:3319–3323CrossRefPubMedGoogle Scholar
  16. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMedGoogle Scholar
  17. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037–1042PubMedGoogle Scholar
  18. Gaffey MJ, Iezzoni JC, Meredith SD, Boyd JC, Stoler MH, Weiss LM, Zukerberg LR, Levine PA, Arnold A, Williams ME (1995) Cyclin D1 (PRAD1, CCND1) and glutathione S-transferase pi gene expression in head and neck squamous cell carcinoma. Hum Pathol 26:1221–1226CrossRefPubMedGoogle Scholar
  19. Ganmaa D, Sato A (2005) The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Med Hypotheses 65:1028–1037CrossRefPubMedGoogle Scholar
  20. Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, Lazarous DF, Pierce L, d’Angelo T, Moscow JA, et al. (1993) A pilot study of pi-class glutathione S-transferase in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 11:49–58PubMedGoogle Scholar
  21. Granja F, Morari EC, Assumpcao LV, Ward LS (2005) GSTO polymorphism analysis in thyroid nodules suggest that GSTO1 variants do not influence the risk for malignancy. Euro J Cancer Prev 14:277–280CrossRefGoogle Scholar
  22. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS (2004) Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210:151–157CrossRefPubMedGoogle Scholar
  23. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650–4656PubMedGoogle Scholar
  24. Hogdall EVS, Hogdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, Vuust J, Norgard-Pedersen B, Kjaer SK (2002) Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significancer in ovarian cancer patients. Anticancer Res 22:1859–1864PubMedGoogle Scholar
  25. Howells RE, Redman CW, Dhar KK, Sarhanis P, Musgrove C, Jones PW, Alldersea J, Fryer AA, Hoban PR, Strange RC (1998). Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 4:2439–2445PubMedGoogle Scholar
  26. Howells RE, Holland T, Dhar KK, Redman CW, Hand P, Hoban PR, Jones PW, Fryer AA, Strange RC (2001) Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer 11:107–112CrossRefPubMedGoogle Scholar
  27. Hu X, Ji X, Srivastava SK, Xia H, Awasthi S, Nanduri B, Awasthi YC, Zimniak P, Singh SV (1997) Mechanism of differential catalytic efficiency of two polymorphic forms of human glutathione S-transferase P1-1 in the glutathione conjugation of carcinogenic diol epoxide of chrysene. Arch Biochem Biophys 345:32–38CrossRefPubMedGoogle Scholar
  28. Iwai K, Mizuno S, Miyasaka Y, MoriT (2005) Correlation between suspended particles in the environmental air and causes of disease among inhabitants: cross-sectional studies using the vital statistics and air pollution data in Japan. Environ Res 99:106–117CrossRefPubMedGoogle Scholar
  29. Johansson AS, Stenberg G, Widersten M, Mannervik B (1998) Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 278:687–698CrossRefPubMedGoogle Scholar
  30. Klaes R, Ridder R, Schaefer U, Benner A, von Knebel Doeberitz M (1999) No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer. J Mol Med 77:299–302CrossRefPubMedGoogle Scholar
  31. Knudsen LE, Loft SH, Autrup H (2001) Risk assessment: the importance of genetic polymorphisms in man. Mutat Res 482:83–88PubMedGoogle Scholar
  32. Koushik A, Robert W, Platt RW, Franco EL (2004) p53 Codon 72 Polymorphism and Cervical Neoplasia A Meta-Analysis Review. Cancer Epidemiol Biomarkers Prev 13:11–22CrossRefPubMedGoogle Scholar
  33. Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, Sellers TA (1999) Prospective study of diet and ovarian cancer. Am J Epidemiol 149:21–31PubMedGoogle Scholar
  34. Lallas TA, McClain SK, Shahin MS, Buller RE (2000) The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev 9:587–590PubMedGoogle Scholar
  35. Langseth H, Kjaerheim K (2004) Ovarian cancer and occupational exposure among pulp and paper employees in Norway. Scand J Work Environ Health 30:356–361PubMedGoogle Scholar
  36. Mannervik B (1985) The isozymes of glutathione S-transferase. Adv Enzymol 57:357–417PubMedGoogle Scholar
  37. Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54CrossRefPubMedGoogle Scholar
  38. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphisms at amino acid residue 72 of human p53. Mol Cell Biol 7:961–963PubMedGoogle Scholar
  39. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T, Lopes C (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156–161CrossRefPubMedGoogle Scholar
  40. Morari EC, Leite JLP, Granja F, Assumpcao LVM, Ward LS (2002) The null genotype of glutathione S-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol Biomarkers Prev 11:1485–1488PubMedGoogle Scholar
  41. Ngan HY, Liu VW, Liu SS (1999) Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer 80:1828–1829CrossRefPubMedGoogle Scholar
  42. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203CrossRefPubMedGoogle Scholar
  43. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10:431–442CrossRefPubMedGoogle Scholar
  44. Pegoraro RJ, Moodley M, Rom L, Chetty R, MoodleyJ (2003) P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 13:444–449CrossRefPubMedGoogle Scholar
  45. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochemistry 300:271–276Google Scholar
  46. Qie M, ZhangY, Wu J (2002) Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao 33:274–275PubMedGoogle Scholar
  47. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ (1998) p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352:871–872CrossRefPubMedGoogle Scholar
  48. Russo D, Marie JP, Zhou DC, Faussat AM, Delmer A, Maisonneuve L, Ngoc LH, Baccarani M, Zittoun R (1994) Coexpression of anionic glutathione S-transferase (GST pi) and multidrug resistance (mdr1) genes in acute myeloid and lymphoid leukemias. Leukemia 8:881–884PubMedGoogle Scholar
  49. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006 Feb 6; [Epub ahead of print]Google Scholar
  50. Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293–7297PubMedCrossRefGoogle Scholar
  51. Shen H, ZhengY, Sturgis EM, Spitz MR, Wei Q (2002) P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 183:123–130CrossRefPubMedGoogle Scholar
  52. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G (2001) Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 22:67–72CrossRefPubMedGoogle Scholar
  53. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 21:229–234Google Scholar
  54. Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, Ando M (2003) Functional characterization of two variant human GSTO1-1s (Ala140Asp and Thr217Asn). Biochem. Biophys Res Commun 301:516–520CrossRefPubMedGoogle Scholar
  55. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, Tsai CH (2002) Prognostic Significance of the proline form of the p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112:116–119CrossRefPubMedGoogle Scholar
  56. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M (2006) Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100:173–178Google Scholar
  57. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB (2004) TP53 mutations in early stage ovarian carcinoma, relation to long-term survival. Br J Cancer 90:678–685CrossRefPubMedGoogle Scholar
  58. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999a) Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 35:226–230CrossRefGoogle Scholar
  59. Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999b) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5:129–134Google Scholar
  60. Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Persp 105:919–926CrossRefGoogle Scholar
  61. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15:583–587PubMedCrossRefGoogle Scholar
  62. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG (2003) Characterization of the human omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 13:131–144CrossRefPubMedGoogle Scholar
  63. Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, Ogawa O, Terachi T, Huang CH, Chiang CP, Yoshida O (1995) Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 86:730–736PubMedGoogle Scholar
  64. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29:697–702CrossRefPubMedGoogle Scholar
  65. Yung WC NG MH, Sham JS, Choy DT (1997) p53 codon 72 polymorphism in nasopharyngeal carcinoma. Cancer Genet. Cytogenet 93:181–182CrossRefPubMedGoogle Scholar
  66. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M (1999) Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354:218–219CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Elaine Cristina Morari
    • 1
  • Andre Bacellar Costa Lima
    • 1
  • Natassia Elena Bufalo
    • 1
  • Janaina Luisa Leite
    • 1
  • Fabiana Granja
    • 1
  • Laura Sterian Ward
    • 1
  1. 1.Laboratory of Cancer Molecular Genetics, Department of Medicine, Medical Sciences FacultyState University of Campinas-UNICAMPCampinasBrazil

Personalised recommendations